S-23
Aliases: S23
Last verified: 2026-09-23
The short version
One of the most potent SARMs — closest to steroids in suppression; also studied as a male contraceptive (full spermatogenesis suppression in rats). Key fact: No controlled human trials exist. Everything known about S-23 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- One of the most potent SARMs — closest to steroids in suppression; also studied as a male contraceptive (full spermatogenesis suppression in rats).
Mechanism of action
High-affinity full AR agonist in muscle/bone.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for S-23. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 10–30 mg/day split (short half-life). The community describes it as "closest to steroids": pronounced growth and dryness, but strong suppression and sometimes aggression; cycles are kept short.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The community describes it as "closest to steroids": pronounced growth and dryness, but strong suppression and sometimes aggression; cycles are kept short.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
10–30 mg oral daily, split into two doses because of the short half-life.
- Cycle:
- 8 weeks, sometimes shorter at the high end of the dose range.
- Break:
- Full SERM-based PCT is treated as mandatory, not optional, given the suppression depth.
The community consensus is that S-23 is the SARM closest to a steroid in effect and in suppression — it was a male-contraceptive candidate in rats. Cycles are kept short and PCT aggressive accordingly.
Human evidence
No controlled human trials exist. Everything known about S-23 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical only (GTX).
Known risks
- Marked HPTA suppression, aggression, lipid changes; no human safety data.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.